1. Home
  2. BWFG vs PRTA Comparison

BWFG vs PRTA Comparison

Compare BWFG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bankwell Financial Group Inc.

BWFG

Bankwell Financial Group Inc.

HOLD

Current Price

$66.73

Market Cap

543.4M

Sector

Finance

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.41

Market Cap

449.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWFG
PRTA
Founded
2002
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
543.4M
449.7M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
BWFG
PRTA
Price
$66.73
$9.41
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$55.00
$19.00
AVG Volume (30 Days)
52.4K
449.1K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
1.52%
N/A
EPS Growth
261.79
N/A
EPS
2.95
0.26
Revenue
$2,826,000.00
$814,000.00
Revenue This Year
$17.64
$1,111.38
Revenue Next Year
$6.21
N/A
P/E Ratio
$22.47
$36.35
Revenue Growth
43.96
N/A
52 Week Low
$40.45
$7.73
52 Week High
$69.59
$11.80

Technical Indicators

Market Signals
Indicator
BWFG
PRTA
Relative Strength Index (RSI) 59.08 59.12
Support Level $65.64 $8.91
Resistance Level $69.41 $10.29
Average True Range (ATR) 1.42 0.42
MACD -0.51 0.08
Stochastic Oscillator 38.39 93.92

Price Performance

Historical Comparison
BWFG
PRTA

About BWFG Bankwell Financial Group Inc.

Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: